http://rdf.ncbi.nlm.nih.gov/pubchem/patent/IE-40825-L
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4c4cb9b5558ad97d3acc0db1113f7727 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D295-15 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D207-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D211-34 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D211-60 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-14 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D295-15 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-275 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-535 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-435 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C231-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C231-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D211-34 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C231-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C67-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-445 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C237-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-165 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D211-60 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D207-09 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-40 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D207-08 |
| filingDate | 1975-03-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 1979-08-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | IE-40825-L |
| titleOfInvention | Ortho alkoxyanilides,a process for their preparation and pharmaceutical compositions containing them |
| abstract | 1458898 Anilides SCIENCE UNION ET CIE SOC FRANCAISE DE RECHERCHE MEDICALE 18 March 1975 [18 March 1974] 11868/74 Heading C2C The invention comprises anilides of the Formula I in which n is 0 to 3; R is H or C 1-6 alkyl, C 2-6 alkenyl or p optionally substituted phenyl- C 1-4 -alkyl; R 2 is C 1-6 alkoxy, C 1-6 alkylthio, halogen or trifluoromethoxy; R 3 and R 4 each are H or C 1-6 alkyl; X and Y each are H or C 1-6 alkyl, or X and Y together with the nitrogen atom to which they are attached form a 3 to 7 membered saturated heterocyclic ring which may contain one or two further heteroatoms, or X and R 3 together with the intervening atoms form a 5 to 7 membered saturated heterocyclic ring, or X and R 4 together with the intervening atoms form a 4 to 6 membered saturated heterocyclic ring which may contain one or two further heteroatoms; and A and B each are H, C 1-6 alkyl. C 1-18 carboxylic acyl, or A and B are both oxygen, or A and B together with the nitrogen atom to which they are attached form a 3 to 7 membered saturated heterocyclic ring and physiologically tolerable acid addition salts thereof. The compounds are prepared by reacting anilines of the Formula II with amino acids of the formula or with reactive functional derivatives thereof, if desired, when R 2 is halogen in the resulting anilides, reacting the products with metal cyanides, alkali metal mercaptides, alkali metal alkoxides or alkali metal trifluoromethoxides, and, if desired, reducing the nitro group. Compounds of Formula I above in which A and B are alkyl or acyl or together with N atom form a saturated heterocyclic ring are obtained by alkylating or acylating the corresponding compounds in which A and B are hydrogen. The compounds may also be prepared by reacting compounds of the formula wherein Z is an arylsulphonyloxy, C 1-6 alkyl sulphonyloxy, trialkylsilyloxy or halogen with amines of the formula and, if desired, reducing the nitro-groups thereof. 3,5<SP>1</SP> - Dichloro - 4<SP>1</SP> - nitropropion - o - anisidide is obtained by reacting 5-chloro-4-nitro-oanisidine with 3-chloropropionyl chloride. Pharmaceutical compositions, suitable for oral, parenteral, rectal, perlingual or percutaneous administration, contain the above anilides or physiologically tolerable acid addition salts thereof in admixture or conjunction with inert pharmaceutical excipients. The compounds possess an inhibitory effect on gastric secretion.n[GB1458898A] |
| priorityDate | 1974-03-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 41.